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Abstract 
Reverse exchange (RE) in dealing with the return, recycle and reuse of products is 
receiving a growing focus. When properly handled, RE in healthcare can deliver an 
economic benefit of cost minimisation and has extensive positive impacts on both human 
health and the environment (Li and Olorunniwo, 2008) but to date, RE research is mostly 
limited to pharmaceutical return. This paper investigates the potential for RE benefits in 
the UK National Health Service (NHS) supply chain for medical devices. Hearing aids 
supplied to adults with hearing loss are used as an illustrative example. This research 
applied a consensus approach through the use of dispersed nominal groups in order to 
obtain qualitative data on information, barriers, solutions and priorities to support 
findings. Findings illustrate that the end user behaviour of returning the device, and the 
requirement by NHS Procurement for manufacturers to meet RE targets are secondary to 
the importance of audiology departments who have the autonomy to design RE processes 
and successfully implement initiatives. A schematic highlighting the information and 
materials flow of the supply chain and the barriers and facilitators to RE is presented for 
hearing aid devices with potential for transferability to other small medical device supply 
chains.  
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1. Introduction 
Sustainable procurement for the public sector and importantly in healthcare has been high 
on the government’s agenda throughout the 21st century (DEFRA 2007; National Audit 
Office, 2013). In 2006, the Sustainable Procurement Task Force which sits within the 
Department of Environment, Food and Rural Affairs (DEFRA) provided a definition of 
sustainable procurement as being:  
 
a process whereby organisations meet their needs for goods, services, works and 
utilities in a way that achieves value for money on a whole life basis in terms of 
generating benefits not only to the organisation, but also to society and the 
economy, whilst minimising damage to the environment (Procuring the Future, 
2006:10).  
 
The aim of this strategy is to configure public sector and government supply chains which 
focus on low carbon, low waste and water efficiencies, to deliver sustainable development 
objectives (DEFRA, 2007). In the private sector and predominately the manufacturing 
arena, the role of supply chains in managing sustainable development have been 
facilitated by reverse exchange (RE) (Schenkel et al., 2015).  
 
The definition of RE includes product design and the product life cycle, encompassing 
all supporting products in the systems including packaging as well as the ‘reverse flow’ 
or recovery processes which include the collection of materials for recycling and disposal, 
commonly associated with reverse logistics (RL) (Rogers and Tibben-Lemke, 1999; 
Govindan, Soleimani and Kannan, 2015). RL is commonly more discussed in the 
literature with RE being a relatively new concept in supply chain management (SCM) 
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that encompasses recovery of the item and usually an exchange element. Reverse flow 
literature has focused on manufacturing based supply chains utilising the lens of RE 
(recovery, reuse, repair, recycle) to gain performance improvement in product flows 
(Esain et al., 2016). In these industrial settings, RE is regarded as an effective competitive 
tool (Chan and Chan, 2008). 
 
In healthcare, RE research is mostly limited to pharmaceutical return (Ritchie et al., 2000; 
Xie and Breen 2012, 2014). In the UK National Health Service (NHS) device return, 
focus is more often on high value or high risk device return (DoH, 2012) however this 
can be expanded to smaller, more common devices to realise benefits. Options for 
upstream entry back into the supply chain for devices, which include replacement, repair 
(or maintenance) or proper disposal can deliver economic benefit and a positive impact 
on the environment (Li and Olorunniwo, 2008). Esain et al. (2016) were the first to 
provide extended literature outlining guidance to public service managers (specific to 
healthcare) to deploy and manage REs. 
 
Enhancing RE in healthcare supply chains is an important step to improving sustainable 
processes for an economically stretched public service. Providing insights into 
implementation issues of RE advances knowledge to a point where insights from other 
reverse flow processes can be applied and practioners can overcome barriers to the 
execution of returning devices. Additionally, the lack and inconsistency of legislation on 
the reuse of devices is problematic for RE in healthcare. 
 
Consequently, this paper investigates the potential for RE benefits in the UK NHS supply 
chain for medical devices. Hearing aids supplied to adults with hearing loss are used as 
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an illustrative example. These devices were chosen because high numbers are in 
circulation and regular checkups with a healthcare professional make them suitable for 
monitoring for return. Hearing aid RE can be generalised to other devices that are issued 
to one patient for their lifetime or the life span of the device, such as insulin pumps, 
asthma inhalers or walking frames. Thus both the process design and refinement and the 
stakeholder involvement, engagement and coordination is transferable. Insights are 
sought for one type of medical device to ensure a practical and valuable focus on real 
facilitators and barriers to implementation by directly studying the supply chain actors 
involved in the provision of the devices.  
 
The research questions (RQs) are: 
 
• What are the barriers to RE for hearing aid devices in the NHS? 
• What are the strategies for overcoming these barriers? 
• How would a RE process be most effectively implemented for hearing aid return 
in the NHS? 
 
 
2. Literature Review 
2.1 Reverse Exchange 
A growing focus has been placed on RL of which RE is a part, to realise economic and 
environmental gains, for example in the automobile repair sector, electronics industry and 
packaging industries. Reverse flow can include recovery, remanufacture, refurbishment, 
replacement, maintenance, reuse, repair, recycle or disposal. A combination of Defee et 
al,’s (2010) reverse SCM definition and Esain et al.’s (2016) RE explanation are used to 
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define RE for this paper as the effective return of a product in order to either dispose of 
it or recover value, while preserving previous met service expectations and delivering 
economic and environmental benefit. In healthcare, reverse flow research is mostly 
limited to pharmaceutical return (Ritchie et al., 2000; Xie and Breen 2012, 2014) because 
of issues with unused medicines in the public domain and need for incineration. Xie et al. 
(2016:194) define RE of medical devices as occurring  
 
when products are returned to source for exchange or final recovery due to 
product replacement (based on patient needs changing), product maintenance 
(the functionality of the product parts need to be checked or repaired) or 
obsolescence (product reaches its natural end of life).  
 
RE activities can affect and are affected by stakeholders such as customers or users, 
governmental organisations, non-governmental organisations, suppliers or other actors in 
the supply chain of the firm. Thus, considering different stakeholders in RE value research 
is important (Schenkel et al., 2015).  Through the development of reverse supply chain 
literature, the existing traditional supply chain allows the exploitation of waste to be 
transformed to resources that can be used again through sustainable activities, such as 
reusing and recycling (Shaharudin et al., 2017). Among the effectiveness that could be 
realised by firms, they include cost savings in operations, improving the relationships 
with customers to encourage repeat use, utilising the recovered products to support the 
production capacity, lowering the buying cost for raw materials, components or sub-
assemblies because less are needed, mitigating the volume of wastes for disposal, 
increasing the commitment towards green practices and reducing the scrap rate 
(Shaharudin et al., 2017). Being a traditional reverse approach, RL now gives way to 
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closed loop supply chains (CLSC) and RE which has a reverse restorative/regenerative 
focus (Batista et al., 2018). But firms do not always exploit the potential of reverse flow 
as the conditions allowing the exploitation remain unclear (Larsen et al. 2018). Initiatives 
such as the reuse and advantages of transit stock items in logistics e.g. returnable transport 
packaging (Yusuf et al., 2017) and CLSC literature outside of the public sector, provide 
a setting for both yielding economic benefits and meeting customer demand for a product. 
The technology capabilities, operational models and associated motivation for the success 
is relevant, especially where inventory management and logistics (certainly not reverse 
flow) is not the core mission of the NHS but have drawn attention and investment as they 
affect service levels and costs (Baffo et al., 2009). 
 
RE incorporates issues such as uncertain timing and quantity of returns, disassembly of 
returned products and the requirement for a RE network (Junior and Filho, 2012). For 
example, specific information systems supporting partner collaboration are needed in a 
reverse flow supply network (Ferguson and Browne, 2001). RE as a research area is well 
served in manufacturing contexts but lacks non-manufacturing perspectives (Kumar et 
al., 2016) and public service insights (Esain et al., 2016). Remanufacturing as part of RE 
lacks practical research and Junior and Filho (2012) found mostly theoretical studies in 
their review of the literature. Xie et al. (2016) and Breen, Xie and Cherrett (2016) have 
the most pioneering papers on RE of medical devices so far with a limited number of 
other studies for specific types of equipment such as wheelchairs (Chouinard et al., 2009). 
Traditionally, many manufacturers approach towards used or end-of-life products was to 
ignore them (Thierry 1995), but RE opens up new possibilities, opportunities and 
challenges. The public sector has a responsibility to be leading by example, so even 
though the recovery value is a major factor in the economic feasibility of the CLSC 
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(Abdallah, Diabat and Simchi-Levi, 2012), there are other benefits to be realised outside 
of economic gains. 
 
There is an expectation that the progression made with hearing aid devices will be 
scalable to other items with similar characteristics, such as healthcare devices that must 
be returned before reissue, but also for items which do not need reissue such as crutches 
for short-term ailments, using process improvements and behavioural influences. 
Research into private sector reverse flow is useful for this in two ways. Firstly, where the 
bi-directional nature of service supply chains whereby providers not only need to handle 
reverse flows in case of service failures, but also when the service is correctly delivered 
ie. they need to get used items back such as in the case of telecommunications equipment 
(Kumar et al. 2016) could be useful to emulate for the NHS. Secondly, where complex 
supply chains are being investigated for items that have been customised online and then 
returned (Batarfi, Jaber and Aljazzar, 2017). 
 
2.2 The NHS Context  
When examining the potential for RE, consideration of the healthcare context is important 
(Radnor and Noke, 2013). In this NHS context, it is difficult to separate the NHS at its 
inception, to that of today, when viewed in headlines over the years. Insufficient 
calculations had been made on the NHS budgets requiring more funding, demand was 
rising, and improvements were required and these issues have been on-going (Klein, 
2013). Funding variations, government initiatives, restructuring, accusations of poor 
quality of care and crisis have appeared to engulf the NHS over the last 70 years. Many 
of the calls made at the start of the NHS, and over subsequent years, such as the need for 
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quality of care, efficiencies and productivity, are still being made (Klein, 2013; Dunn, 
McKenna and Murray, 2016). 
 
There is an ongoing pressure for the NHS to save money through a combination of cost 
cutting, productivity improvements and innovation in service delivery in the context of 
new commissioning structures developing as a result of the Health and Social Care Act 
2012 (Sanderson et al., 2015). Procurement has received an enhanced focus in recent 
years in the NHS where evaluation of service options, configuration, delivery, refinement, 
integration and the discussion of new pathways is in evidence (NHS Commissioning 
Board, 2012). Despite this focus, by 2016, the publication of the Carter Review was still 
critiquing NHS productivity and illustrated the potential for procurement to contribute to 
an estimated £5 billion in savings expected each year by the period 2020/21 (Gov.UK, 
2016). A key element of the Carter Review focused on procurement and the need for 
savings but within the report there is no consideration of reuse or recycle and building 
this mechanism into supplier agreements.  
 
NHS Trusts spend around £9 billion on the procurement of goods and services and £6 
billion is spent within the acute sector with the breakdown of spending being 1/3 on 
common goods and services, 1/3 on medical consumables and 1/3 on high cost medical 
devices (Gov.UK, 2016). A new approach to the purchase of expensive medical devices 
is required as a figure of £500 million is given for spend on devices such as implantable 
heart defibrillators, bespoke prosthetics and bone-anchored hearing aids (NHS England, 
2016). Potential expected savings from the Carter Review, estimated out of the £5 billion 
per annum expected savings, £1 billion could be saved through enhanced procurement 
activities, although a figure of £770 million is perceived to be more achievable (Gov.UK, 
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2016). The challenge for commissioners is to decide where those savings will be derived 
from. 
 
2.3 Importance of Audiology Provision in the UK 
Although hearing aids have been available for free on the NHS since its inception in 1948, 
a number of commissioning groups as a result of pressure on NHS budgets and spending, 
have proposed cuts to spending on hearing aid devices, despite these devices being the 
only option for those with hearing loss (Action on Hearing Loss, 2016). These proposed 
cuts have fuelled newspaper headlines decrying NHS cruelty (Campbell, 2015) and the 
fuelling of a dementia epidemic (Knapton, 2016). 
 
Hearing loss is estimated to affect 10.7 million adults in England and delays in 
identifying, diagnosing and managing hearing loss can have a significant impact on the 
health and well-being of those affected (NHS England, 2011). Loneliness, social isolation 
and dementia are associated with hearing loss. There is expected to be a rise in those 
affected by hearing loss due to ongoing global conflict affecting military service 
personnel, an aging demographic and the use of personal devices (Monitor, 2015). The 
cost to the UK economy due to lost output is estimated at £25 billion by the International 
Longevity Centre UK (ILC, 2014). The World Health Organisation (WHO) estimate that 
360 million people worldwide are affected by disabling hearing loss, with resulting costs 
(including labour and output losses) of 750 billion international dollars1 which does not 
include the cost of hearing devices (WHO, 2017). 
 
 
                                                 
1 WHO (2017) define an international dollar as that which would buy in any cited country a comparable 
amount of goods and services a U.S. dollar would buy in the United States.  
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2.4 Return of Devices in the NHS 
Although there is evidence of pressures to reduce NHS budgets for devices such as 
hearing aids, the societal and health implications of these decisions means that 
alternatives must be considered. Innovation in service delivery can include reverse flows 
in the supply chain where there is potential for lessons to be learned from activities and 
initiatives implemented elsewhere to enable the adoption of good practice in the NHS 
(Hinrichs et al., 2014). Public sector bodies such as the NHS are being encouraged to 
stimulate sustainability in the private sector by leading by example. An advantage they 
have is in the volume of the requirement of goods, as they can leverage their influence as 
major procurers of good and services (Brammer and Walker, 2011). In the Carter Review, 
sustainability is considered in terms of energy efficiencies, carbon footprint and food 
waste but this is not explicit in new procurement mandates and supplier management 
processes that are to evolve as a result of the review (Gov.UK, 2016). As sustainable 
procurement in practice and literature develops with gusto, the reverse flow of these 
goods back into the supply chain for various purposes demands attention. Given the 
aforementioned limitations on RE work on NHS devices (Xie et al., 2016), there is scope 
for further research in this area. 
 
Recent investigations have shown the NHS has no standard across its trusts for the return 
of medical equipment, devices and apparatus. When investigating wheelchair allocation 
and return in Canada, Chouinard et al. (2009) found the same issue. Recently, the NHS 
has received negative media attention for its lack of RE inciting fury through the tabloid 
press who published photographs of NHS equipment such as crutches, mobility aids and 
limb braces in a skip destined for landfill in 2016. Some trusts have implemented 
initiatives to gather up unwanted items for return, showing small but promising examples. 
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For instance, one Local Health Service in Devon encourages people to return NHS 
equipment instead of throwing it away or leaving it at a Recycling Centre by offering 
drop off points and collection services to ensure it gets into the right reverse chain for 
reissue, refurbishing or recycling (Devon County Council, 2018). In 2016 the BBC’s One 
Show assisted with a crutch amnesty (BBC, 2016) despite their first reporting of these 
initiatives in 2003 (BBC News, 2003). There is even evidence of small businesses 
stepping in to fix the failures of the RE in the NHS, such as Terry’s Zimmers, also in 
Devon who refurbishes and reissues mobility aids to prevent unnecessary landfill. All in 
all, a centralised initiative is lacking. Exploration of the challenges in the NHS of RE not 
being implemented and how it might be achieved is needed and investigating just one 
piece of equipment will help to map the issues to scale up to other apparatus. Hearing aids 
are issued to one person at a time for the lifespan of the product (damage or obsolescence) 
or for as long as the patient needs the device, making them similar to other equipment 
issued by the NHS that could be tracked and returned.  
 
 
2.5 Legal Statutes affecting reuse 
Despite a public sector agenda considering sustainability (Brammer and Walker, 2011), 
there are challenges for considering reuse in the form of legislatory requirements. There 
are a range of relevant legal statutes related to the return of devices in the NHS offering 
limited guidance. These include motions under the Medicines and Healthcare Products 
Regulatory Agency (MHRA) and are more specifically the Management of Medical 
Devices Prior to Repair, Service or Investigation DB2003(05). The Introduction to 
Device Bulletin: Single-use Medical Devices: Implications and Consequences of Reuse 
DB2006(04) discusses reuse of devices but question the benefits and advise against reuse 
stating: 
13 
 
 
The reprocessing and reuse of single-use medical devices is a longstanding practice, 
although the MHRA advises against this. Users often justify the reprocessing of 
such devices on the basis of economic and environmental benefits. These perceived 
benefits are questionable as many of the processes required to ensure that the device 
is safe and fit for its intended purpose cannot be undertaken by the reprocessor (a 
person who undertakes the reprocessing of a medical device). Many single-use 
devices are also reused without adequate evaluation of the increased risks to 
patients. 
 
Despite advising against reuse, in April 2015 MHRA (2015:4) published an updated 
version of ‘Managing Medical Devices’ stating in the introduction that this guidance is 
for those who manage reusable medical devices by stating:  
 
The purpose of this document is to outline a systematic approach to the acquisition, 
deployment, maintenance (preventive maintenance and performance assurance), 
repair and disposal of medical devices. Guidance on medical device training is also 
provided. It is intended primarily for people in hospital and community based 
organisations that are responsible for the management of reusable medical devices, 
to help them set up and develop systems that promote the use of the medical devices 
for safe and effective health care. Many of the principles of this guidance document 
may apply to all medical devices. 
 
Although in discussion of high value devices, the Department of Health note that often 
these cannot be reused, but this is not the case for all as there is discussion of insulin 
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pumps being reconditioned and reused for other patients (DoH, 2012). However, despite 
the discussion of reusable medical devices in the MHRA quotation, there are no 
recommendations in managing suppliers in the acquisition of medical devices which will 
offer the potential for reuse and recycle (MHRA, 2015). Much of the advice is restricted 
to service, repairs and preventative maintenance as well as disposal as it is stated ‘there 
is no legislation which specifically covers the resale or reuse of medical devices or 
equipment’ (MHRA, 2015:49). Nonetheless, the overall goal for CLSCs is minimum 
wastage and maximum cost efficiencies and for the context of NHS supply chains, single 
use devices (SUD) for single patients is debated. For example, Hailey et al. (2008:430) 
find that although ‘studies of variable quality suggested that SUD reuse could be safe and 
effective, and would give cost savings, if there were no adverse events […] there is 
insufficient evidence to establish the safety, efficacy and cost-effectiveness of reusing 
SUDs’ and hence do not support the reuse of devices designed for single use. The type of 
device under discussion is important though, as the reuse of needles and syringes can 
carry a high risk of infection compared to reuse of crutches and asthma inhalers. The 
MHRA in the United Kingdom does advise reuse of SUDs, but this is not consistent 
across Europe, Asia, Australia and North America (Popp et al., 2010).  
 
Consequently, in considering these elements, the study investigates the area of RE and 
healthcare, a progressive area of research suggested by Kumar et al. (2016) and Esain et 
al. (2016). Practical issues with the implementation of the RE initiative are considered, a 
suggestion supported by Junior and Filho (2012, 2016). Specifically, there is a focus on 
context specific hearing aid RE, a type of study recommended by Radnor and Noke 
(2013). Research gaps in the literature have been identified, related to the practical 
reasons why RE is not occurring in the NHS beyond that the service is stretched resource-
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wise. Thus, our RQs are 1.) What are the barriers to RE for hearing aid devices in the 
NHS? 2.) What are the strategies for overcoming these barriers? 3.) How would a RE 
process be most effectively implemented for hearing aid return in the NHS? 
 
 
2. Methodology 
Radnor and Noke (2013) encourage researchers to embrace the diversity and contextual 
nature of public sector operations management to provide rich in-depth knowledge to 
understand complexity. Contextually, the uniqueness of the UK NHS is recognised but 
in-country healthcare studies are also very useful (eg. For Italy see Lega, Marsilio and 
Villa, 2013; for Quebec, Canada see Chouinard et al., 2009 and see Aptel and Pourjalali 
(2001) for a US/French hospital logistics comparison). Concentrating our study on one 
type of device (hearing aids) for RE provides insights into real facilitators and barriers to 
implementation. Given the already discussed limitations of RE literature (Beamon and 
Fernandes, 2004; Junior and Filho, 2012; Junior and Filho, 2016), this is further 
compounded by a private sector and RL focus specifically, and the use of mathematical 
modelling (Turrisi, Bruccoleri and Cannella, 2013; Batarfi, Jaber and Aljazzar, 2017). 
This research contributes through a qualitative, empirical study of RE.  
 
3.1 Dispersed nominal groups 
In order to investigate the potential for RE benefits in the NHS supply chain for medical 
devices, a consensus methodology which has been popular in medicine and health 
research since the 1960s was employed (Jones and Hunter, 1995). Qualitative consensus 
methodologies have their origins in grounded theory and comprehensive process analysis 
(Hill et al., 2005). Moving beyond typical operations and supply chain management 
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(OSCM) methodologies has been recommended in order to better understand complex 
social and behavioural elements of OSCM (Boyer and Swink, 2008). Dispersed nominal 
groups (DNG) were used to obtain qualitative information from target groups most 
closely associated with the problem area of returning devices in the NHS (see Figure 1). 
Working with nominal groups is supported where there is a lack of scientific knowledge 
or in this case, a lack of knowledge and understanding of barriers and facilitators for RE 
in hearing aid supply chains (Jones and Hunter, 1995). Nominal group research is phased  
firstly to gather information and then identify the problem [Phase A] and secondly to 
discuss and develop strategies before going on to establish priorities [Phase B] (Delbecq 
and Van de Ven, 1971; Van de Ven and Delbecq, 1972). Although focus groups and 
Delphi studies are similar to this approach, the two distinct phases of using nominal 
groups which include feedback, idea generation and priorities, provides greater benefits 
to the research process (Potter et al., 2004).  
 
3.2 Data collection 
Semi-structured interviews were conducted by one of the research team who is 
experienced in this methodology and is an audiology subject expert as advocated by Fink 
et al., 1984 and Jones and Hunter, 1995. However, they are not expert in the subject matter 
of RE and were therefore able to maintain a degree of objectivity in determining the 
outcome or solution (Glaser, 1980). The interviews were conducted with key stakeholders 
involved in the hearing device supply chain from an individual to a policy level for an 
NHS Trust in the South of England. Audiology practice and organisation is highly similar 
across England due to centralised training services and hearing aid manufacturers are 
national, spanning the UK. See Table 1 for the roles of participants who included 
audiologists (and managers), hearing aid manufacturers and NHS Procurement staff 
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working in small device (hearing aids) procurement. This group provided insights into 
the issue and management of devices, role and relationships with suppliers and the impact 
of NHS procurement decisions on other groups, which meant patients were beyond the 
scope of this research (see Figure 1). Consequently, these targeted groups of professionals 
are legitimate samples for research where this focuses on their expertise (Saunders and 
Townsend, 2016) and this recognition of expertise is a key element of the nominal group 
approach as part of a consensus strategy (Fink et al., 1984; Jones and Hunter, 1995).  
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Figure 1 Scope of data collection reach 
 
 
 
Table 1. Interviews conducted by staff role 
 
Role 
Number of 
interviews across 2 
phases 
Interview code 
(A=first phase) 
(B=second phase) 
NHS Procurement Team 6 NHSP_A/NHSP_B 
Hearing Aid Manufacturers  6 Manf_A/Manf_B 
Audiology Managers/Audiologists 8 Aud_A/Aud_B 
   
 
3.3 Coding and Analysis 
Coding was undertaken using the first and second rounds of dispersed nominal group data 
and assembled under four key headings: information>barriers>solutions>priorities 
(Delbecq and Van de Ven, 1971; Van de Ven and Delbecq, 1972; Glaser, 1980; Fink et 
al., 1984). The use of the dispersed nominal group approach focused on the stakeholders 
identified in Table 1 meaning they were able to independently input, verify data and 
support findings leading to the presentation of this consensus data. This process is 
illustrated in Table 2 and further expanded on in the findings section in Figure 2.  
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Table 2. Phased coding and data analysis 
Information 
– Phase A 
Barriers 
– Phase A 
 
Solutions/Strategies 
– Phase B 
 
Priorities 
– Phase B 
 
RE Process for 
hearing aids (all 
groups) 
Lack of formal 
process. Informal 
process between 
Audiology and 
Manufacturer 
only. 
Formalised process 
for RE including 
procurement 
involvement in 
tracking and 
refurbishment 
potential.  
Embed RE in 
contractual 
requirements 
between suppliers 
and customers. 
Public sector ‘lead 
by example’. 
Cost/Economic 
benefit 
Misalignment of 
tender cycles. 
Positive potential 
cost-implications of 
RE identified. 
Incentives for 
reuse and recycle. 
Strategic 
requirements 
‘Some’ framework 
requirements 
(MHRA). 
Reuse feasible. 
Considered as SUD 
but they are reusable. 
Adherence to 
MHRA. 
Formalised 
guidance within 
legal statutes 
instead of 
ambiguity. 
Behaviours Not made clear to 
users that 
equipment belongs 
to NHS and is 
borrowed. 
Clarity of ownership, 
encourage behavior 
of return for 
recycle/reuse. 
Formal process 
designed to 
capture return of 
hearing aids. 
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3. Findings   
The three key stakeholder groups’ involvement has allowed the mapping of the RE of 
NHS hearing devices. The facilitators and barriers to RE of hearing aid devices which has 
been validated through our consensus approach are presented. Suggested implementation 
of the RE initiative using audiology departments as the primary leading stakeholder is 
presented in the schematic (Figure 2).  
 
 
4.1 Key stakeholders 
What became clear across every group was that the audiology departments were identified 
as the primary leading stakeholder in terms of their relationships with NHS Procurement, 
suppliers and having direct patient contact. This was illustrated in discussions with 
manufacturers and audiologists who discussed how refurbishment is carried out between 
audiology departments and manufacturers. Although the NHS has implemented 
electronic ordering systems, products which come back into the supply chain are not 
tracked as this bypasses NHS central systems and is arranged between audiologists and 
manufacturers: 
 
“Refurbishment is done between department and manufacturer. With the new electronic 
ordering systems, the NHS supply chain can keep track of what is ordered by each centre 
but only for new devices” (NHSP_A_1). 
 
The priority for NHS Procurement is the purchase of new devices. For a reverse flow of 
equipment they are not currently, nor are there any plans to be central to the process.  
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4.2 Facilitators to RE implementation 
Identification of the key roles and relationships between actors in the hearing device 
supply chain, enabled the identification of facilitators and barriers to RE implementation. 
The facilitators to implementation were illustrated by three key examples in the hearing 
aid supply chain which included the economics of refurbishment, strategic requirements 
through the feasibility of refurbishment and the consideration of social norms.  
 
1. Economics of refurbishment 
Participants identified that there is a cost saving for audiology departments who have 
systems in place to refurbish devices as they can be re-issued at approximately two thirds 
the cost of new. The average cost of a new hearing aid is £58 and the cost of a refurbished 
aid is £40. There is also a potential incentive for manufacturers where the margin on 
reconditioning exceeds that on new devices. Audiology staff recognised that under the 
current climate, refurbishment was highly viable and valuable: 
 
“It’s cheaper if we have something refurbished. There is no choice really. It’s an 
economic imperative” (Aud_A_1).  
 
2. Strategic requirements 
There are some framework requirements for suppliers to refurbish old devices such as the 
Medical Device Directive to ensure there is no cross contamination through handling 
devices or contamination of bodily fluids. This cross contamination is usually mitigated 
by sterilisation but this is not suitable for hearing aids due to internal components. 
Suppliers confirmed that hearing aids are considered a SUD. One manufacturer gave the 
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example of how customer reconditioning meant the possibility of cross contamination 
where apparently clean aids were found to be contaminated: 
 
“In general terms, hearing aids are considered as single patient use, i.e. they are 
reusable but only after undergoing a rigorous and effective refurbishment. I can 
clearly confirm that even the cleanest of looking hearing aids when opened 
demonstrate evidence of use whether through dirt and grime or ingress of ear 
wax. The risk of cross contamination – although low- is there” (Manf_A_2). 
 
Contradictory advice appears to exist however on what is feasible in terms of cleaning 
and recycling hearing aids. Staff referred to the role of the internet in providing 
information on this and how there is a lack of consistency in concluding what is best 
practice for those looking for advice: 
 
“Google searches of “reuse of medical devices”, “Reuse of hearing aids”, and 
“sterilise hearing aids” all throw up interesting articles and sources of 
information, all provide comment, guidance, and direction – none are 
conclusive. It is key to distinguish guidance for the cleaning of a hearing aid for 
use by the same person to that for reuse by another individual” (Manf_A_1). 
 
 
3. Social norms  
Devices would be more likely to be returned by patients where it is accepted that hearing 
aids are on loan and must be returned. This reinforcement that aids are on loan, is 
perceived by audiologists to be welcomed by patients as they are aware of challenging 
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fiscal times for health service providers. Despite these social norms, there is uncertainty 
as to where and if hearing aids are returned which creates challenges in determining the 
level of returns being received by the manufacturer: 
 
“There is no refurbishment or recycling in the private sector as far as I am aware. 
Public healthcare need to lead on this with the challenge that there is no demand 
for it from patients at the moment. We rarely get asked what they should do with 
their old aids. If people became more accustomed to returning what actually 
belongs to the NHS this would be a driver to successful return. Equipment across 
the NHS is issued [temporarily] to patients, not given to them and if this message 
was clearer we might see better return rates” (Aud_A_4). 
 
 
4.3 Barriers to RE implementation 
Some of the facilitators can also be identified as barriers as what should happen is not 
necessarily current practice as the processes to support this are lacking. Barriers to the 
return of devices impacting this facilitation were also identified and these cover four key 
areas including strategic misdirection where technology and policy does not support RE, 
the lack of process, the lack of behavioural incentive and the pace of technological 
change. 
 
1. Strategic misdirection  
The NHS focus latterly on procurement has shown issues emerge over inventory 
management, obsolescence and a need to consolidate purchasing across healthcare trusts 
(Gov.UK, 2016). Currently, in managing inventory and obsolescence, the NHS is striving 
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to manage efficient supply and new device issue, however, there are currently no targets 
for device return or reissue, except for timescales within supply chain tender 
specifications. The onus is on the NHS Trusts to ‘schedule’ aids for reconditioning and 
manage this, not centralised procurement, but there is recognition that further work is 
needed to support the provision and management of hearing devices. The purchasing 
power of the NHS, as one of the world’s biggest spending organisations with a planned 
expenditure for 2016/17 of £120.611bn (NHS Confederation, 2017), could be better 
utilised to encourage manufacturers and suppliers to support RE. During the consensus 
validation, an audiologist observes: 
 
“The information flow here is correct and goes beyond just ordering new devices. 
NHS Procurement need to incorporate return, refurbishment and recycling into 
contracts for suppliers. Audiologists can’t do it alone and we certainly can’t send 
things back with no basic processes to do so” (Aud_B_2) 
 
As strategic requirements have been identified as facilitators to RE of hearing aids, NHS 
Procurement confirms that this is a current barrier to it too as it will affect procurement 
in terms of additional processes of tracking and refurbishment potential: 
 
“We do need to make some substantial changes to how hearing aids are provided 
but I don’t know what effect this will have on procurement because of tracking, 
costs and refurbishment potential. It all really needs to be driven by procurement” 
(Aud_A_4).   
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This uncertainty looks set to continue as although the Carter Review (Gov.UK, 2016) has 
identified the importance of sustainable practices in the NHS, this has been discussed in 
generalist terms and has not provided specific illustrations in terms of medical devices 
and how these will be managed in the scope of procurement. Currently RE processes in 
hearing devices are not considered in the procurement process of medical devices by the 
NHS centrally and there was no indication that this was to change as the procurement 
mandate was for supply and use of new devices: 
 
“We don’t get involved in reverse logistics […] our mandate is to ensure the 
efficient supply and use of new devices” (NHSP_A_2).  
 
Moreover, suppliers provide evidence that it is not part of their strategy either: 
 
“We recycle based on practicality coupled with expense. So if there is no business 
sense to outlay more on the recovery than is viable for value, we won’t […] 
Plastics and rubber parts are not recycled. This is down to cost but also on the 
risk of cross-contamination. With any medical device cross-contamination is a 
key factor, depending upon the make-up of the device it may limit the extent of 
cleaning and sterilisation which will impact what can be recycled for what 
purpose” (Manf_A_3) 
 
They confirm this in the consensus validation that a green agenda is lacking when it comes 
to devices: 
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“My opinion on the medical device itself is that there is not a green agenda. There 
is on the supply chain, packaging, information, stocks and even processes but not 
on the actual device itself. The focus there is functionality, meeting customer need, 
and compliance with regulatory requirements” (Manf_B_3). 
 
 
2. Lack of Process  
Within the NHS, control of medical devices lies with the provider but when this device 
is issued to the patient at the clinic, the control is handed over to the patient for the 
duration of use of the device. The provider regains control at the end of the life of the 
device, for example when the device should be returned. Commonly, this is not made 
explicit to the patient and so patients are often issued with new devices, with previous 
versions still in their possession: 
 
“Patients are not incentivised to return the device for replacement, maintenance, 
repair or proper disposal” (Aud_A_1). 
 
Consequently, this means there is no formal process or mechanism for capturing patients 
who return devices, either through clinical appointments or even in attendance at their 
general practitioner at a later date: 
 
“There are tracking issues […] individual serial numbers are not tracked and 
linked to patients when it comes to refurbishment” (Aud_A_4). 
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3. Lack of behavioural incentive  
Despite clear community incentives that patients were familiar with in terms of expected 
behaviours in managing household wastes and the disposal of electronic devices, hearing 
aids were not considered in this manner. The lack of tracking process identified 
previously, means that the need to return the device is not explicit and therefore, patients 
are not incentivised to return devices for reconditioning or proper disposal: 
 
“Patients don’t hand back the original hearing aid when they have a new one fitted 
and this has not always been encouraged” (Aud_A_2). 
 
The potential of psychological utility is not being exploited. To date, it was evident from 
the participants in this study that there is a lack of pressure on the NHS to foster RE from 
the public, also an observation made by Esain et al. (2016). 
 
 
4. Pace of technological change   
Part of the challenge in managing current device usage and inventories is the risk of 
obsolescence due to the pace of technological change and the wide variety of products 
available for use. This is fueled by the misalignment of the tender and reconditioning 
cycles which means the reconditioned aids can be at risk of obsolescence: 
 
“The tender cycle operates over a shorter period than the reconditioning cycle to 
incorporate advances in technology. This means reconditioned aids become 
obsolete” (Manf_A_2). 
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This poses a risk to the key facilitator of cost incentive of reissue which has been 
identified. However, other benefits of RE can be realised through recycling, for example, 
even if technological change has rendered the device obsolete.  
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Figure 2. Framework for RE of hearing aids in NHS 
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5. Discussion 
Brammer and Walker (2011) identified cost as the main barrier to public sustainable 
procurement and top management buy-in as the main facilitator. Our study on RE in healthcare 
shows cost as one of the reasons both for and against the return on devices depending on the 
stakeholder and the audiology department (and manager of this department) are identified as a 
key player in the implementation of RE where NHS Procurement has a reduced role in the 
purchase and no role in the return of the devices. There is currently a blend of autonomy 
between NHS Procurement and audiology departments. For example, NHS Procurement are 
tasked with new purchases where they can achieve advantages of centralisation such as quantity 
discounts (Crama, Pascual and Torres, 2004), reduced duplication of effort, economics of scale 
and economics of scope. However, the current recommendations for the centralisation of 
procurement services and associated supplier contracts in the Carter Review means that going 
forward, this will be a challenge to currently held audiology autonomy (Gov.UK, 2016). Even 
recent discussions over Sustainability and Transformation Plans (STPs) in the NHS do not 
focus on centralised services, giving Trusts localised powers (NHS England, 2017).  
 
 
5.1 Barriers to RE for hearing aid devices in the NHS 
The barriers to RE for hearing aid devices in the NHS (RQ1) are categorised as strategic 
misdirection, lack of process, lack of behavioural incentive and pace of technological change. 
Figure 2 presents these in more detail for each stakeholder. It also shows the materials flow 
from suppliers to audiology departments to patients and back again through audiology 
departments to suppliers. Although the extent that this is occurring is patchy due to the barriers. 
The information flow is similar except that NHS Procurement are best placed to encourage 
suppliers to remanufacture hearing aids which could be done through supplier development 
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programmes (Zhang, Pawar and Bhardwaj, 2017). Additionally, information should be 
transferred back up the chain to NHS Procurement for target setting and management of the 
reverse flow of the devices. The NHS could be realising the potential of innovative business 
models in the reverse supply chain, by looking beyond simply returning to the point of origin 
(Beh et al. 2016). The Department of Health as a wider context actor also has a part to play in 
this strategic pressure.  
 
 
5.2 Strategies for overcoming barriers 
To implement RE for hearing aid devices, strategies for overcoming the barriers are identified 
(RQ2). Firstly the mix of responsibility should be utilised for power advantages over local 
requirements. A blend of centralised and decentralised operations is often advantageous 
(Munson, 2007). Secondly, procurement should take more of a direct role in formulating return 
policies into contracts. For example, as NHS Procurement has purchasing power in the supply 
chain, they may add value through the enforcement of requirements to RE through formal 
contracts, whereby the audiology department will operationally run the process. There has been 
some debate on what kind of contracts best support supply chain coordination in the scope of 
reverse flow items (Govindan, Popiuc and Diabat, 2013) but that they do play a positive role 
(Guo et al. 2017). Thirdly, strong strategic messages from the senior management and official 
channels for how to implement initiatives in healthcare are needed (Böhme et al., 2016).  
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5.3 RE process implementation 
Audiologists and manufacturers should design a suitable process for the RE even though there 
is conflicting information on the extent to the refurbishment allowed (RQ3). Audiologists need 
to play a role in explaining to patients that the aids are on loan and withholding new allocations. 
The patients are immersed in the device issue processes due to their often active participation 
and providers need to set up different procedures to manage the returns of customer items, 
according to the process phase when the return occurs, such as refit on the basis of a previous 
return (Kumar et al., 2016). Our behavioural findings of patients’ motivation to return, while 
secondary, can be attributed to consumer motivation towards RE such as Yuan et al.’s (2016) 
study in the electronics industry. As customer non-compliance is not a primary cause of reverse 
systems breakdowns (Breen, 2006) the change in behaviour needed is important but the process 
infrastructure needs to be resolved first. The NHS does not have the issue of ‘upsetting’ patients 
and risk losing trade by asking for their equipment back as could be the case in the private 
sector (Breen, 2006), so the context is unique. There is a wider debate to be had here - for 
example, there is research to suggest that patients would accept medicines that were still in 
their packaging and hence considered suitable for reuse, if they were displaced from pharmacy 
stock, or returned from a patient (Alhamad, Patel and Donyai, 2018). We have not directly 
researched the patient voice and thus not concluded on patient views on reusing hearing aids, 
but instead considered the barriers to return of the devices. Thus there is scope for more work 
to be conducted on whether patients would use reconditioned hearing aids of the NHS did this. 
Additionally, whether the patient would be told that they had been repaired and reconditioned 
or whether they would be distributed to them as new without their knowledge would need to 
be considered. Moreover, whether they would need to know should be investigated. The public 
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sector potentially have the starting position of a true circular economy perspective based on 
whether a choice should be given. 
 
Networked systems will be required for data management of hearing aid allocation (Ferguson 
and Browne, 2001). Evidence suggests that when innovative and suitable tools support the 
proper management of the information and material reverse flow, legislation is satisfied 
and improvements in supply chain performance are achieved (Turrisi, Bruccoleri and 
Cannella, 2013). Legislation is ambiguous on reusing SUDs because the MHRA advises 
against, rather than forbids it, thus legislation has failed to keep up with technological advances. 
MHRA is based on EU directives from the 1990s and 2000s.  In 2012 the European 
Commission proposed new Regulations ([EU] 2017/745 and [EU] 2017/746) but these were 
only formally adopted on 5th April 2017 and will apply after a transition period of three and 
five years respectively. (EU) 2017/745, section 38 notes that reprocessing of SUDs should only 
be conducted where permitted by national law and also by the manufacturer, but later supports 
that member states can allow reprocessing by health institutions as long as the safety and 
performance levels are equivalent to the original SUD (European Commission, 2017). 
 
Where refurbishment cannot occur, recycling should be managed. NHS Procurement and 
patient behaviour have supporting roles compared to the autonomy of the audiologist to 
effectively carry out RE. The evidence shows that suppliers are reluctant with no incentive to 
employ RE and need the encouragement from all three groups to act. Figure 2 shows that the 
end user behaviour of returning the device, and the NHS Procurement requirement for 
manufacturers to do so are only superficial reasons for the lack of RE. Actually, the audiology 
departments who have autonomy to design these processes are where the focus for RE 
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implementation should be directed. It is not uncommon in the private sector that drivers for 
reverse benefits are driven at ‘firm’ level rather than supply chain level (Masi et al., 2018). 
 
There is not a closed loop between the patient, audiology department, hearing aid manufacturer 
and NHS Procurement for hearing aid recycling or reuse, nor does there need to be to get RE 
initiated. Although purchasing of new aids is performed via NHS Procurement, and they set 
out some standards for decontamination and turnaround time for recycling and refurbishment, 
the process is actually negotiated directly between individual departments and hearing aid 
manufacturers. This looks set to continue with the localised approach of STPs (NHS England, 
2017). Thus, NHS Procurement may have a powerful overarching opportunity to specify 
requirements to suppliers nationally which would be useful, but the audiology departments 
have the autonomy for negotiation and process design at the local level meaning 
implementation and success is more likely.  
 
 
6. Conclusion 
As our health care systems continue to struggle with increasing demands for their services and 
many organisations are looking for ways in which to improve the design of their systems and 
work more effectively across the health care economy (Wikner, 2017), the focus of this study 
is the reverse flow of the supply chain. The barriers to RE for hearing aids in the UK are 
identified and a suggested framework for implementation of RE of the devices using key 
players is presented. The study has specifically focused on issues with the practical 
implementation of a RE process and directly employs those NHS practioners dispensing the 
devices. The resultant process has been identified as most effective due to the facilitating nature 
of the audiology department between the end user and manufacturer, with the centralised NHS 
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Procurement team assisting with better enforcement and incentives for manufacturer 
cooperation. To achieve initiatives such as this, there is a need to apply integrated SCM 
practices in NHS Procurement (Sanderson et al., 2015) and for increased interdisciplinary work 
across health-care management and SCM (Hinrichs et al., 2014).  
 
This research seeks to raise the profile of RE in the NHS devices supply chain, focusing on 
potential financial outcome and sustainability. The framework provides a positive step towards 
a reverse supply chain with minimum wastage and maximum cost efficiencies for device return 
in the NHS. Identifying barriers and suggesting ways to overcome these makes the framework 
ready for empirical testing. Our proposals support discussion by Radnor and Noke (2013) who 
highlight that although private sector practices are transferred into the public sector, 
adaptability is key as is consideration of ownership and value. This is evident in this work 
through the adaptation of RE device supply chains, rather than endorsing a CLSC. Adaptation 
allows focus on the social practices of ownership of RE processes where audiologists are 
identified as a key stakeholder in currently facilitating this and the value of RE processes to be 
initially identified and established by centralised NHS Procurement which will support 
overarching sustainability policies. 
 
 
7. Limitations and future research 
The study extends the literature beyond the manufacturing derived RE concept to develop an 
understanding of the NHS, supplier and patient role in preserving and co-creating value in RE 
in UK healthcare. This study has focused on the hearing aid supply chain which may not be 
representative of other device supply chains in the NHS. It is appreciated that the disposal of 
hearing aids, being so small, has a relatively minor impact on landfill masses. However, the 
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process management of the issue of the device is illustrative of other medical equipment and 
further investigation into manufacturer-led initiatives and provider-led initiatives should be 
conducted to devise the most effect strategies and motivations for the change in process (Guo 
et al., 2017; Batista et al., 2018). The mapping developed represents only the first step in 
investigating the NHS supply chain and any interventions based on it will need to be tested and 
validated. However, there is scope for further research in this area and there is potential for the 
mapping to be applied to other devices once the process is tested. The contextual nature of the 
NHS is recognised, including the importance of cost efficiencies and behavioural implications 
on the value of ‘free’ and support similar studies carried out in other country healthcare 
provision. 
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